Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes. It occurs when high blood sugar levels damage small blood vessels in the retina, the light-sensitive tissue ...

Diabetic macular edema (DME) is a complication of diabetes that occurs when fluid builds up in the macula, the part of the retina responsible for central vision. This can lead to blurred or double ...

Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.

The complete response letter (CRL) specifies that the current dosage duration of aflibercept is still safe but extending the ...

It is being developed as an eye drop to treat the retina to offer a non-invasive treatment alternative for diabetic macular edema (DME). This route of administration enables easy access to ...

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

It is being developed as an eye drop to treat the retina to offer a non-invasive treatment alternative for diabetic macular edema (DME). This route of administration enables easy access to treatment ...

Oculis Holding completes enrollment in both DIAMOND phase 3 clinical trials of OCS-01 in diabetic macular edema: Zug, Switzerland Monday, April 14, 2025, 15:00 Hrs [IST] Oculis Ho ...